In this week’s episode of “The Top Line,” Fierce Pharma’s Zoey Becker sits down with Bobby Sheng, the CEO of Bora Pharmaceuticals, to discuss the concept of “friend-shoring” in drug manufacturing.

"Friend-shoring" involves conducting manufacturing processes in countries considered friendly or allied. Sheng discusses the criteria for deeming a country “friendly” and explores whether this strategy could help address drug supply shortages.

To learn more about the topics in this episode:
Bora plants its flag in the US with $210M acquisition of generics manufacturer Upsher-Smith
Emergent, pivoting away from CDMO business, sells Baltimore plant to acquisitive Bora for $30M

In this week’s episode of “The Top Line,” Fierce Pharma’s Zoey Becker sits down with Bobby Sheng, the CEO of Bora Pharmaceuticals, to discuss the concept of “friend-shoring” in drug manufacturing.
"Friend-shoring" involves conducting manufacturing processes in countries considered friendly or allied. Sheng discusses the criteria for deeming a country “friendly” and explores whether this strategy could help address drug supply shortages.
To learn more about the topics in this episode:
<ul>
<li><a href="https://www.fiercepharma.com/manufacturing/bora-plants-its-flag-us-210m-acquisition-generics-manufacturer-upsher-smith" data-cke-saved-href="https://www.fiercepharma.com/manufacturing/bora-plants-its-flag-us-210m-acquisition-generics-manufacturer-upsher-smith">Bora plants its flag in the US with $210M acquisition of generics manufacturer Upsher-Smith</a></li>
<li><a href="https://www.fiercepharma.com/manufacturing/emergent-pivoting-away-cdmo-sells-baltimore-site-acquisitive-bora-30m" data-cke-saved-href="https://www.fiercepharma.com/manufacturing/emergent-pivoting-away-cdmo-sells-baltimore-site-acquisitive-bora-30m">Emergent, pivoting away from CDMO business, sells Baltimore plant to acquisitive Bora for $30M</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement